Instructions & Warnings For UK Patients (Read First)

Concerned about low blood sugar or interactions with other medicines?

Repaglinide (INN: repaglinide, often branded as NovoNorm in Europe) is a prescription‑only meglitinide used to control post‑meal blood glucose in type 2 diabetes.

Key risks include hypoglycaemia, which can present as sweating, tremor or confusion, and a severe interaction with the fibrate gemfibrozil that may cause prolonged hypoglycaemia.

Use caution with significant liver or kidney problems and start at low doses for older adults because hypoglycaemia risk is greater.

If you drive or operate machinery, avoid hypos and follow DVLA guidance about reporting recurrent severe hypoglycaemia.

Practical daily steps: take repaglinide 0–30 minutes before a main meal and skip the tablet if you skip that meal.

Keep fast‑acting carbohydrate (glucose gel, sugary drink) to hand and tell your pharmacy and GP about any new medicines.

Check MHRA and NHS sources regularly for safety updates and ask a pharmacist at Boots, LloydsPharmacy or Superdrug for counselling if unsure.

Basic Novonorm Information

• INN (International Nonproprietary Name): Repaglinide
• Brand Names Available In United Kingdom: NovoNorm (Europe); other global brands include Prandin, Gluconorm, Surepost—local UK listings not specified
• ATC Code: A10BX02
• Forms & Dosages: Tablets 0.5 mg, 1 mg, 2 mg
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription Only (Rx)

Everyday Use And Best Practices

Morning Vs Evening Dosing

Many patients ask whether to take a full set of doses each day or concentrate on mornings.

Repaglinide is a short‑acting, mealtime glucose regulator taken 0–30 minutes before each main meal to reduce prandial glucose spikes.

Typical tablet strengths are 0.5 mg, 1 mg and 2 mg and dosing is usually before breakfast, lunch and the evening meal unless the prescriber advises otherwise.

Avoid taking only a single daily dose unless your clinician specifically prescribes that regimen.

For evening dosing consider later UK meal habits and alcohol, since alcohol can increase hypoglycaemia risk overnight.

Taking With Or Without Meals (UK Diet Habits)

Repaglinide must be taken in relation to food, so if you skip a meal you skip that dose.

UK routines such as tea with biscuits or late weekend dinners mean plan doses around when you actually eat rather than fixed clock times.

If you expect a late meal, time the tablet so it precedes the actual food intake to ensure the drug acts when glucose rises.

Carry a small checklist for mealtime dosing: dose time, tablet strength, recent carbohydrate intake and blood glucose reading.

• If Meal Skipped: skip the dose for that meal — do not double up later.
• If You Take A Late Snack: take the dose 0–30 minutes before the snack only if it is a main meal as advised by your clinician.

Safety Priorities

Who Should Avoid It (MHRA Warnings)

Not everyone with diabetes should take repaglinide.

Absolute contraindications include type 1 diabetes, diabetic ketoacidosis and known hypersensitivity to repaglinide or excipients.

Concurrent use of gemfibrozil is a critical contraindication because it can cause severe, prolonged hypoglycaemia.

Caution is necessary in significant hepatic impairment and marked renal dysfunction, and elderly patients often need lower starting doses.

Pregnancy and breastfeeding require specialist discussion about alternatives and risks.

Activities To Limit (Driving, Work Safety)

Driving and safety‑critical work should be approached cautiously until you know how repaglinide affects you.

DVLA rules require reporting recurrent severe hypoglycaemia and your clinician may need to adjust therapy before you can continue driving.

• Contraindications Checklist: type 1 diabetes; diabetic ketoacidosis; hypersensitivity; gemfibrozil co‑use.
• Work/Driving Steps: log hypoglycaemia episodes; inform GP and employer if hypos recur; follow DVLA guidance.

Dosage And Adjustments

General Regimen (NHS Guidance)

What should patients expect when starting repaglinide?

Adults often start at 0.5 mg with each main meal if HbA1c is below 8% and 1 mg per meal if HbA1c is 8% or above.

Titration can proceed weekly up to a single dose of 4 mg and a total daily maximum of 16 mg, guided by blood glucose and HbA1c results.

Always take tablets 0–30 minutes before a meal and skip doses for skipped meals.

Never double the next dose to make up for a missed one.

Special Cases (Elderly, Comorbidities)

Elderly patients should start at the lowest dose (typically 0.5 mg) and titrate slowly with close monitoring for hypoglycaemia.

In renal impairment begin at 0.5 mg with cautious upward titration while monitoring glucose closely.

Severe hepatic impairment is a contraindication; mild to moderate liver dysfunction requires low starting doses and careful observation.

Children: safety and efficacy have not been established and repaglinide is not generally recommended in paediatric practice.

• Starting/Titration Table: start 0.5–1 mg per meal; increase weekly; max single dose 4 mg; max daily 16 mg.
• When To Contact GP: recurrent hypos, unexpected weight change, rising HbA1c despite adherence.

User Testimonials

Positive Reports From UK Patients

Patients often report better control of post‑meal spikes and flexibility for irregular meal patterns with repaglinide.

Many comment that timing a short‑acting tablet before meals fits social eating better than a fixed long‑acting drug.

Community pharmacists at Boots and LloydsPharmacy are frequently praised for clear counselling during initiation and dose changes.

Some people report fewer late‑night hypos when timing and portion sizes are well matched to the dose.

Common Challenges (Patient.info, NHS Forums)

Common concerns on Patient.info and NHS forums include hypoglycaemia when meals are delayed or missed and interactions when new medicines are started.

Gastrointestinal side effects and the need for frequent finger‑prick monitoring during titration are commonly mentioned.

Practical issues include arranging GP repeats and prescription charge differences between England and the devolved nations.

• Top Patient Tips: always carry fast carbs, keep a glucose log, check interactions with a pharmacist, plan doses around real meals.
• Pros Vs Cons Summary: Pros — prandial control, meal flexibility; Cons — hypoglycaemia risk, frequent dosing, monitoring burden.

Buying Guide

Pharmacy Sources (Boots, LloydsPharmacy, Superdrug)

In the UK repaglinide (branded as NovoNorm or generics) is prescription‑only and is normally obtained via a GP prescription.

Collect from high‑street pharmacies such as Boots, LloydsPharmacy and Superdrug or via NHS online prescription services when available.

Community pharmacists can offer advice, check interactions and arrange a Medicines Use Review where appropriate.

Online pharmacies must be GPhC‑registered and require a valid NHS or private prescription for lawful dispensing.

Price Comparison (NHS Prescription Charge Vs Private)

Prescription charges apply in England unless you are exempt, while prescriptions are generally free in Scotland, Wales and Northern Ireland.

Private prescription prices vary between chains and online pharmacies, and generics are typically cheaper than branded NovoNorm.

In our online pharmacy, novonorm is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

• Verify Online Pharmacy: check GPhC number, clear contact details and prescription requirements before ordering.
• Cost Tip: ask your pharmacist about generic repaglinide to reduce expense on private prescriptions.

What’s Inside And How It Works

Ingredients Overview

The active ingredient is repaglinide, available as 0.5 mg, 1 mg and 2 mg tablets.

Excipients vary by manufacturer, so review the patient information leaflet for allergy or intolerance information.

Repaglinide belongs to the meglitinide (glinide) class and is classified under ATC code A10BX02.

Mechanism Basics Explained Simply

Repaglinide is a rapid‑acting insulin secretagogue that stimulates pancreatic beta cells to release insulin in response to food.

It targets prandial glucose rather than lowering fasting glucose throughout the day.

The short action window blunts the post‑meal glucose rise and fits patients with irregular meal timings better than some longer‑acting secretagogues.

• How It Helps After A Meal: increases insulin for a short window, reduces prandial spike, allows meal‑time flexibility.

Main Indications

Approved Uses (MHRA Listing)

Repaglinide is authorised for adults with type 2 diabetes as an adjunct to diet and exercise to control post‑meal hyperglycaemia.

It is useful where mealtime glucose control is the primary target or where meal timing varies from day to day.

MHRA/EMA list repaglinide (NovoNorm) as an authorised oral glucose‑lowering agent in the meglitinide class.

Off‑Label Uses In UK Clinics

Off‑label use is uncommon, but clinicians may consider repaglinide when metformin is contraindicated or not tolerated.

It may also be used as short‑term bridging therapy around procedures requiring brief, titratable glucose control.

Repaglinide is not indicated for type 1 diabetes or diabetic ketoacidosis.

• Approved Vs Not Approved: Approved for type 2 diabetes prandial control; not approved for type 1 or ketoacidosis.
• Switch Checklist: consider switching if hypos recur, if liver/renal status changes, or if HbA1c remains unacceptable.

Interaction Warnings

Food Interactions (Alcohol, Tea/Coffee)

Alcohol increases the risk of hypoglycaemia when combined with repaglinide, so avoid excess drinking around doses.

Caffeine in tea or coffee does not markedly change repaglinide levels but can mask symptoms such as palpitations.

Always take repaglinide relative to the actual meal, not the expected or planned meal time.

Drug Conflicts (MHRA Yellow Card Reports)

Avoid gemfibrozil because it may cause severe and prolonged hypoglycaemia when used with repaglinide.

Other drugs that affect CYP3A4 or CYP2C8 can alter repaglinide concentrations; check with a pharmacist before starting new medicines.

Report suspected interactions or adverse effects to the MHRA Yellow Card scheme to support post‑marketing safety monitoring.

Latest Evidence And Insights

Key UK & EU Studies 2022–2025

Recent European and UK registry data continue to support repaglinide as an effective short‑acting agent for prandial control.

Comparative studies show similar HbA1c reductions to other insulin secretagogues when appropriately dosed and with reduced prolonged hypoglycaemia versus older sulfonylureas.

Safety reviews reiterate careful use in hepatic impairment and highlight interactions with fibrates as critical safety priorities.

Practical Takeaways For Patients

Expect close glucose monitoring and dose titration when starting under NHS care, with pharmacist counselling frequently included.

Newer evidence favours repaglinide for flexible meal patterns but not as first‑line therapy when metformin is tolerated and appropriate.

• Study Findings: effective for prandial spikes; lower prolonged hypo risk than some sulfonylureas.
• Discussion Checklist For GP: intended target (prandial control), monitoring plan, potential side effects and interactions.

Alternative Choices

NHS Prescribing Alternatives With Pros/Cons Checklist

Alternatives on the NHS include metformin, sulfonylureas (glimepiride, gliclazide), DPP‑4 inhibitors (sitagliptin) and SGLT2 inhibitors (empagliflozin).

Metformin is first‑line for most and offers weight neutrality and cardiovascular data but may be poorly tolerated by some patients.

Sulfonylureas are effective but carry higher prolonged hypoglycaemia risk, while DPP‑4 inhibitors are well tolerated but less focused on prandial spikes.

When To Consider Switching

Consider switching if recurrent hypoglycaemia persists despite dose adjustments, if liver or renal function changes, or if HbA1c remains uncontrolled.

Lifestyle factors that make regular mealtime dosing impractical may also prompt a change to alternative classes or insulin.

• Decision Flow: assess hypos, review labs, discuss lifestyle and monitoring, consider alternatives.

Regulation Snapshot

MHRA Approval & NHS Prescribing Framework

Repaglinide is authorised in the EU/UK market as NovoNorm and as generics under ATC A10BX02 and is prescription‑only.

UK prescribing follows NHS formularies and local clinical guidance, with GPs assessing indication, comorbidities and interactions before issuing a prescription.

MHRA monitors post‑marketing safety and updates contraindications and warnings as needed.

Reporting Side Effects (Yellow Card)

Report suspected adverse events to the MHRA Yellow Card scheme online or via the Yellow Card app to help detect rare safety signals.

Pharmacists and GPs commonly assist patients to complete Yellow Card reports and will use the data when assessing drug safety.

• How To Report: visit the MHRA Yellow Card website, use the app or ask your pharmacist/GP for help.

FAQ Section

Common UK Patient Questions

Can I drink alcohol if I take repaglinide?

Alcohol increases the risk of hypoglycaemia; avoid excess and monitor closely around dosing.

What if I miss a meal after taking a dose?

If you miss the meal, skip that dose and resume with the next main meal; do not double doses.

Is repaglinide available on the NHS?

Yes, repaglinide is available by prescription on the NHS; prescription charges apply in England unless exempt.

What should I carry for low blood sugar?

Carry fast‑acting carbohydrate (glucose gel or juice), an ID card stating you take repaglinide and your GP contact details.

• Quick Checklist To Carry: glucose gel/juice; diabetes ID; GP phone number; small carb snack as backup.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Pharmacists at Boots, LloydsPharmacy and Superdrug should counsel patients to take repaglinide 0–30 minutes before meals and to carry fast carbs.

Counselling should include avoidance of gemfibrozil and excessive alcohol and a review of other medicines including OTC items.

Ask about a Medicines Use Review if you would like a dedicated session to cover interactions and side effects.

NHS Patient Support Advice

Your GP should arrange initial follow‑up and blood glucose/HbA1c checks during titration and refer to diabetes education programmes as needed.

Consider attending DESMOND or local NHS diabetes education to learn meal planning and hypo recognition.

Keep a simple home log of pre‑ and post‑meal glucose, doses and any hypoglycaemic events to share with your diabetes team.

• Pharmacy Counselling Points: dosing relative to meals; hypo recognition and treatment; interaction checks.
• NHS Support Services: GP review, DESMOND/education classes, community pharmacy Medicines Use Review.

Delivery Across United Kingdom